Compare ResMed Inc. (RMD) vs Workiva Inc (WK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ResMed Inc. vs Workiva Inc — how do they compare? ResMed Inc. trades at $230.05 (market cap $31.89B), while Workiva Inc trades at $73.25 (market cap $4.01B). The key difference: ResMed Inc. is far larger — about 8× Workiva Inc's market cap, and ResMed Inc. pays a 1.16% dividend while Workiva Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold ResMed Inc. for 51 Days and Workiva Inc for 21 Days on average.
| RMD | WK | |
|---|---|---|
Market Cap | $31.89B | $4.01B |
Volume | 618,314 | 1,301,708 |
Sector | Health | Technology |
52-Week High | $275.96 | $93.31 |
52-Week Low | $182.82 | $44.31 |
Typical Hold Time | 51 Days | 21 Days |
Enterprise Value | $31.24B | $3.99B |
Dividend Yield | 1.16% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ResMed (RMD) trades at $226.73, up 0.33% on the day, with a bullish technical signal supported by moving averages. The company reported strong earnings beats in recent quarters, with Q3 2026 results pending. Revenue grew to $5.15 billion in 2025, with a net income margin of 26.94%, while cash flow from operations reached $1.75 billion. Recent news highlights an upcoming earnings report and positive analyst commentary on growth prospects.
The outlook is positive, driven by consistent earnings outperformance and a consensus price target of $242.70, implying upside. Key risks include competitive pressures and ongoing legal investigations. Institutional interest remains strong, with recent stake increases by funds. The stock's valuation metrics, such as a P/E of 21.74, appear reasonable given growth expectations.
Workiva (WK) trades at $73.69, up 3.02% with strong technical momentum and bullish moving averages. The company shows impressive revenue growth with 2026 revenue reaching $966 million and net income turning positive at $47 million. Recent earnings beats and AI product innovations at Amplify 2026 conference highlight operational strength. Analyst sentiment remains overwhelmingly positive with 16 buy ratings and an $86 consensus price target.
WK presents a compelling growth story with improving profitability and strong analyst support, though elevated valuation multiples and technical overbought conditions warrant caution. The stock's 88.89% buy rating and 16.7% upside to consensus target suggest continued optimism, but investors should monitor execution of AI initiatives and competitive pressures in the regulatory technology space.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →About Workiva Inc
Workiva is a leading provider of cloud-based platforms for complex reporting and compliance. It enables organizations to connect and manage data across financial reporting, ESG (Environmental, Social, and Governance), and GRC (Governance, Risk, and Compliance), serving as a single source of truth for auditable, transparent disclosures to regulators and stakeholders.
Read more on WK →
